More biosim­i­lar use could've saved Medicare and ben­e­fi­cia­ries $84M in 2019, HHS OIG says

In the near­ly 7 years since biosim­i­lars were first ap­proved in the US, the sto­ry has been one of lack­lus­ter up­take, amid a grow­ing fa­mil­iar­i­ty …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA